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Background
Given the important role played by hepatitis viruses in
the development of liver fibrosis we consider it neces-
sary to evaluate markers of disease progression and
instruments for staging of fibrosis in patients coinfected
with hepatitis B and D viruses (HBV, HDV).
Methods
We performed a cohort study to assess markers of disease
progression and staging of liver fibrosis through noninva-
sive tests at three different time points over the course of
HBV and HDV coinfection.
Results
We assessed data from 64 patients (of which 27 were males
- 42%) with a median age of 54±14 (range: 23 to 64 years).
The median fibrosis was 0.44±0.23 and the median
necroinflammatory activity was 0.54±0.24.
The median FIB-4 score was 1.89±3.23 at the second
visit versus 1.26±2.07 at the third visit. The median APRI
score was 1.18±1.67 at the second visit compared to 1.79
±2.53 at the third visit (p=0.05, 95%CI: 0.0389, 0.43681).
Regression analysis showed a correlation between
FibroTest (considered the gold standard in this study, in
the absence of histology data from liver biopsy), FIB-4
(p=0.43) and APRI (p=0.011).
Conclusion
Periodic assessment of patients with viral hepatitis is
needed, with close monitoring of fibrosis progression and
liver function. Noninvasive markers and scores for liver
fibrosis are yet to be validated for patients with HBV and
HDV coinfection, but the data from this cohort of
patients show promising results, with both APRI and
FIB-4 positively correlating with FibroTest.
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